NCT03153163View on ClinicalTrials.gov

Study of the Pharmacokinetics and Safety of Trastuzumab Emtansine in Chinese Participants With Locally Advanced Inoperable or Metastatic HER2+ Breast Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

June 20, 2017

Primary Completion Date

September 27, 2018

Study Completion Date

September 27, 2018

Conditions
Breast Neoplasms
Interventions
DRUG

Trastuzumab Emtansine

Trastuzumab emtansine will be administered by IV infusion at a dose of 3.6 milligrams per kilogram (mg/kg) of body weight, every three weeks (Q3W) until death, disease progression or unmanageable toxicity.

Trial Locations (1)

200032

Fudan University Shanghai Cancer Center; Medical Oncology, Shanghai

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT03153163 - Study of the Pharmacokinetics and Safety of Trastuzumab Emtansine in Chinese Participants With Locally Advanced Inoperable or Metastatic HER2+ Breast Cancer | Biotech Hunter | Biotech Hunter